Inactive Instrument

Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eli Lilly Completes Purchase of Sigilon Therapeutics in Cash Deal MT
Eli Lilly Completes Acquisition of Sigilon Therapeutics MT
Sigilon Therapeutics, Inc. Announces Board Changes CI
Sigilon Therapeutics, Inc.(NasdaqGM:SGTX) dropped from NASDAQ Composite Index CI
Sigilon Therapeutics, Inc.(NasdaqGS:SGTX) dropped from S&P TMI Index CI
Eli Lilly and Company completed the acquisition of remaining 91.56% stake in Sigilon Therapeutics, Inc. from Flagship Ventures Fund V, L.P. and Flagship Pioneering Special Opportunities Fund II, L.P., managed by Flagship Pioneering and others. CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Canaccord Genuity Adjusts Price Target on Sigilon Therapeutics to $30 From $6, Maintains Buy Rating MT
North American Morning Briefing : China Data -2- DJ
North American Morning Briefing : Tesla Bounce -2- DJ
Morgan Stanley Adjusts Price Target on Sigilon Therapeutics to $21 From $7, Maintains Equalweight Rating MT
BTIG Downgrades Sigilon Therapeutics to Neutral From Buy MT
Sector Update: Health Care Stocks Advancing Late Thursday MT
Sector Update: Health Care Stocks Higher Thursday Afternoon MT
Top Midday Gainers MT
Top Stories at Midday: US Q1 GDP Revised Higher; Jobless Claims Post Surprise Drop; Powell Reiterates Comments; BioXcel Therapeutics Tumbles MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Sector Update: Health Care MT
Traders Cheer After Bank Stress Test Results, Lifting US Equity Futures MT
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments RE
Top Premarket Gainers MT
Eli Lilly to Acquire Sigilon Therapeutics in Deal Potentially Worth More Than $300 Million; Sigilon Shares Surge MT
Eli Lilly to Buy Chronic Disease-focused Sigilon Therapeutics MT
Eli Lilly to Acquire Sigilon Therapeutics DJ
Eli Lilly Agrees to Acquire Sigilon Therapeutics for up to $309.6 Million MT
Chart Sigilon Therapeutics, Inc.
More charts
Sigilon Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company's Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company's lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). It is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. It also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
More about the company
  1. Stock
  2. Equities
  3. Stock Sigilon Therapeutics, Inc. - Nasdaq
  4. News Sigilon Therapeutics, Inc.
  5. Morgan Stanley Adjusts Sigilon Therapeutics Price Target to $2 From $4.50, Maintains Equalweight Rating